TNSN93012A1 - Conception, clonage et expression d'anticorps monoclonaux humanises contre l'interleukine-5 humaine - Google Patents

Conception, clonage et expression d'anticorps monoclonaux humanises contre l'interleukine-5 humaine

Info

Publication number
TNSN93012A1
TNSN93012A1 TNTNSN93012A TNSN93012A TNSN93012A1 TN SN93012 A1 TNSN93012 A1 TN SN93012A1 TN TNSN93012 A TNTNSN93012 A TN TNSN93012A TN SN93012 A TNSN93012 A TN SN93012A TN SN93012 A1 TNSN93012 A1 TN SN93012A1
Authority
TN
Tunisia
Prior art keywords
monoclonal antibodies
humanized monoclonal
human interleukin
cloning
expression
Prior art date
Application number
TNTNSN93012A
Other languages
English (en)
Inventor
Chou Chuan-Chu
J Murgolo Nicholas
S Abrams John
Jenh Chung-Her
E Petro Mary
E Silver Jon
Tindall Stephan
T Windsor William
J Zavodny Paul
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of TNSN93012A1 publication Critical patent/TNSN93012A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UN ANTICOPRS MONOCLONAL EST PREVU QUI SE LIE SPECIFIQUEMENT A L'INTERLEUKINE-5 HUMAINE. SONT EGALEMENT PREVUS UN HYDRODOME QUI PRODIT L'ANTICORPS MONOCLONAL ; DES ADN COMPLEMENTAIRES QUI CODENT LES REGIONS VARIABLES DES CHAINES LOURDE ET LEGERE D'UN L'ANTICORPS MONOCLONAL ET LEUR CDR ; LES ANTICORPS MONOCLONAUX HUMANISES ; ET LES COMPOSITIONS PHARMACEUTIAUES COMPRENANT L'ANTICORPS MONOCLONAL OU DES ANTICORPS ANTI- IDIOTYPIQUES DIRIGES CONTRE LUI, LES ANTICORPS MONOCLONAUX HUMANISES, LES FRAGMENTS DE LIAISON, LES COMPOSITIONS OU DES PROTEINES DE LIAISON A UNE SEULE CHAINE QUI SONT DERIVEES DE L'ANTICORPS ET UN SUPPORT PHYSIOLOGIQUEMENT ACCEPTABLE
TNTNSN93012A 1992-02-06 1993-02-05 Conception, clonage et expression d'anticorps monoclonaux humanises contre l'interleukine-5 humaine TNSN93012A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83284292A 1992-02-06 1992-02-06

Publications (1)

Publication Number Publication Date
TNSN93012A1 true TNSN93012A1 (fr) 1994-03-17

Family

ID=25262763

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN93012A TNSN93012A1 (fr) 1992-02-06 1993-02-05 Conception, clonage et expression d'anticorps monoclonaux humanises contre l'interleukine-5 humaine

Country Status (21)

Country Link
US (1) US6451982B1 (fr)
EP (1) EP0625201A1 (fr)
JP (2) JPH07505767A (fr)
KR (2) KR0150060B1 (fr)
CN (1) CN1077991A (fr)
AR (1) AR248044A1 (fr)
AU (1) AU683836B2 (fr)
CA (1) CA2129445A1 (fr)
CZ (1) CZ291039B6 (fr)
FI (1) FI943635A (fr)
HU (1) HUT67943A (fr)
IL (1) IL104620A (fr)
NO (1) NO942912L (fr)
NZ (1) NZ249633A (fr)
PL (1) PL176393B1 (fr)
RU (1) RU94045919A (fr)
SG (1) SG49597A1 (fr)
SK (1) SK280610B6 (fr)
TN (1) TNSN93012A1 (fr)
WO (1) WO1993016184A1 (fr)
ZA (1) ZA93779B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ249633A (en) 1992-02-06 1995-12-21 Schering Corp Monoclonal and humanised antibodies to interleukin-5, their production, use and methods for producing humanised antibodies.
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
ES2277336T3 (es) * 1994-12-23 2007-07-01 Smithkline Beecham Corporation Antagonistas de il-5 recombinantes utiles en el tratamiento de enfermadades mediadas por il-5.
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
ES2233974T3 (es) * 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7141653B2 (en) * 2002-03-29 2006-11-28 Schering Corporation Human monoclonal antibodies to interleukin-5
CA2957200C (fr) * 2002-10-16 2020-05-26 Gen-Probe Incorporated Compositions et methodes de detection du virus du nil occidental
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
AU2003298187B2 (en) 2002-12-17 2010-09-16 Merck Patent Gmbh Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US8192736B2 (en) 2004-10-28 2012-06-05 Kyowa Hakko Kirin Co., Ltd Remedy for endometriosis
EP3072522B1 (fr) 2005-01-06 2019-04-24 Novo Nordisk A/S Traitements de combinaison anti-kir et procédés
IL296666A (en) 2005-03-23 2022-11-01 Genmab As Antibodies against 38cd for the treatment of multiple myeloma
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
DK2152290T3 (da) 2007-04-30 2014-08-18 Glaxosmithkline Llc Fremgangsmåder til indgivelse af anti-il-5-antistoffer
WO2009120927A2 (fr) 2008-03-28 2009-10-01 Smithkline Beecham Corporation Procédés de traitement
US20110229903A1 (en) * 2008-10-23 2011-09-22 Ulrich Goepfert Determination of immunoglobulin encoding nucleic acid
ES2720136T3 (es) 2010-12-22 2019-07-18 Teva Pharmaceuticals Australia Pty Ltd Anticuerpo modificado con semivida mejorada
US9580501B2 (en) 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
US9677018B2 (en) 2013-01-09 2017-06-13 Thyssenkrupp Industrial Solutions Ag Process for the production of synthesis gas from hard coal
EP3191513B1 (fr) 2014-09-08 2020-06-24 Cephalon, Inc. Utilisation de reslizumab pour traiter un asthme éosinophilique modéré à sévère
TWI750133B (zh) 2015-08-24 2021-12-21 美商葛蘭素史密斯克萊有限責任公司 生藥組成物
EP3634467A4 (fr) 2017-06-06 2021-07-28 GlaxoSmithKline LLC Compositions biopharmaceutiques et procédés pour patients pédiatriques
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
US11224653B2 (en) 2017-08-24 2022-01-18 Cephalon, Inc. Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
KR20200059239A (ko) * 2017-09-29 2020-05-28 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Ｉｌ－５ 항체, 이의 항원 결합 단편 및 이의 의학적 적용
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
IL92180A (en) * 1988-11-03 1997-04-15 Schering Corp Pharmaceutical composition for preventing or reducing eosinophilia
WO1990005144A1 (fr) 1988-11-11 1990-05-17 Medical Research Council Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2041271A1 (fr) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptides analogues aux proteines de la grande famille des immunoglobines
NZ249633A (en) 1992-02-06 1995-12-21 Schering Corp Monoclonal and humanised antibodies to interleukin-5, their production, use and methods for producing humanised antibodies.

Also Published As

Publication number Publication date
EP0625201A1 (fr) 1994-11-23
US6451982B1 (en) 2002-09-17
JP2000210097A (ja) 2000-08-02
AU683836B2 (en) 1997-11-27
SG49597A1 (en) 1998-06-15
CA2129445A1 (fr) 1993-08-07
IL104620A (en) 2000-02-29
JPH07505767A (ja) 1995-06-29
AU3656093A (en) 1993-09-03
HUT67943A (en) 1995-05-29
NO942912D0 (fr) 1994-08-05
ZA93779B (en) 1993-08-05
FI943635A0 (fi) 1994-08-05
FI943635A (fi) 1994-08-05
IL104620A0 (en) 1993-06-10
PL176393B1 (pl) 1999-05-31
WO1993016184A1 (fr) 1993-08-19
RU94045919A (ru) 1996-11-10
CZ291039B6 (cs) 2002-12-11
SK280610B6 (sk) 2000-05-16
AR248044A1 (es) 1995-05-31
CN1077991A (zh) 1993-11-03
SK91894A3 (en) 1995-02-08
NO942912L (no) 1994-10-06
HU9402293D0 (en) 1994-10-28
CZ191094A3 (en) 1994-12-15
KR0150060B1 (ko) 1998-08-17
KR950700413A (ko) 1995-01-16
NZ249633A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
TNSN93012A1 (fr) Conception, clonage et expression d'anticorps monoclonaux humanises contre l'interleukine-5 humaine
BG109311A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNFAL, AND HIS APPLICATION
DE69636450D1 (de) PEPTIDE UND PEPTIDOMIMETIKA MIT STRUKTURELLER ÄHNLICHKEIT MIT p53 UND DIE DIE p53-FUNKTION AKTIVIEREN
MY109957A (en) Improved antibodies to plasmodium falciparum
DK0724456T3 (da) CD40-Antistoffer
MX9704897A (es) Secuencias del anticuerpo anti-idiotipo monoclonal recombinante 3h1 relacionadas con el antigeno carcinoembrionico humano.
PT941121E (pt) Preparados farmaceuticos liofilizados, estaveis, de anticorpos monoclonais ou policlonais
DE68925226T2 (de) Monoklonale Antikörper
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
HUP0004639A2 (hu) Chlamydia fehérje, génszekvencia és ezek alkalmazása
GR3020610T3 (en) Monoclonal antibodies against tumor associated antigen, their preparation and use
DE69233125D1 (de) Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
DE3751319T2 (de) VERWENDUNG UND ZUSAMMENSETZUNG ZUR VERBESSERUNG DES "TARGETING" VON ANTIKöRPERN, ANTIKöRPERTEILEN, SOWIE KONJUGATE DERSELBEN.
EP0770624A3 (fr) Peptide pouvant induire une réponse immune contre le cancer de l'estomac et agent contenant ce peptide pour la prévention ou le traitement du cancer de l'estomac
DE69333952D1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
DK0817650T3 (da) Syntetiske peptider og farmaceutiske sammensætninger, der omfatter disse, til behandling af systemisk lupus erythematosus
FI20095269A (fi) Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli
CA2107329A1 (fr) Anticorps recombinants anti-virus de l'immunodeficience humaine
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
GB2333295A (en) Modified protein G and fragments thereof